Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

March 05, 2009

WINSTON-SALEM, N.C. - New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

An advance copy of the study appears online this week in the Journal of Neurology, the official publication of the European Neurological Society. It is scheduled to appear in a future print issue.

Prior to this study, physicians knew that administering intravenous immunoglobulin, or IVIg, could cause stroke or heart attack, but it was unclear when those serious side effects occurred.

"Stroke or heart attack has always been considered a fairly rare complication, but it's a catastrophic one," said James B. Caress, M.D., an associate professor of neurology and the study's lead researcher. Before this study, it was difficult for doctors to counsel patients about their risk for stroke or heart attack from IVIg treatment because previous reports could not identify which patients were at the highest risk, he added.

IVIg - used in patients with autoimmune disorders, such as multiple sclerosis, and with immunodeficiencies - is a drug made from human blood components. In patients who have an autoimmune disease, in which the body forms antibodies that attack its own tissues, IVIg can suppress the detrimental effects of those antibodies. In patients with advanced cancer, where the immune system is damaged from the tumor or chemotherapy, the drug boosts the immune system to stave off infections.

For the study, researchers looked at the medical records of 19 patients who had a stroke or heart attack after receiving IVIg. They also reviewed the records of 38 patients who were the same ages as those 19 patients, but who received IVIg treatment and did not have a stroke or heart attack. The patients, who had an average age of 71 years, received the treatment between August 1998 and May 2004. The researchers compared information about the two groups, including gender and race, the reason the patients received IVIg treatment, dosage, previous exposure to the drug, and the patients' risk factors for stroke and heart attack.

Researchers found that no single cardiovascular risk factor increased the chance of having a stroke or heart attack after IVIg treatment. However, the likelihood of having such an event appeared to increase slightly when the patient had two or more risk factors and, when four or more risk factors were present, patients were 10 times more likely to have a heart attack or stroke within two weeks of receiving IVIg, according to the study's findings.

Cardiovascular risk factors include coronary artery disease, cigarette use, high blood pressure, previous stroke or arterial thrombosis, diabetes and high cholesterol.

Neither the race nor gender of the patient affected the risk of stroke or heart attack, the study showed.

In 2003, Caress and a team of Wake Forest researchers published a paper in Neurology, the journal of the American Academy of Neurology, reporting the experiences of 16 patients who suffered a stroke during or immediately after IVIg infusions.

The latest study expands on that report.

"Prior to 2003, other investigators had reported stroke and heart attack due to IVIg, but these complications were believed to be extremely rare," Caress said. "Now we know that having just one or two cardiovascular risk factors does not result in a major increase in risk for heart attack or stroke after IVIg treatment. But if the patient has three or four of these risk factors, the chance of having a serious complication is substantially higher."

Since 2003, the U.S. Food and Drug Administration has required that IVIg manufacturers add a statement about the risk of stroke and heart attack to their products, so most physicians are now aware of the uncommon complication. It is still unclear, however, what causes the dangerous side effects, Caress said.

Still, the current study gives physicians and patients some direction when considering IVIg treatment, he added.

"I feel good about recommending the treatment, even to older patients, unless they have several cardiovascular risk factors," Caress said.

Wake Forest University Baptist Medical Center

---

---

	Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease (Postgraduate Medicine) by JTE Multimedia Chronic kidney disease (CKD) is a recognized risk multiplier for the development of cardiovascular disease (CVD), with CVD events representing the leading cause of morbidity and mortality in patients with CKD. The nature of CKD as a risk state relates both to the nature of CKD and the antecedent development of CVD. In addition, patients with CKD have increased rates of multiple conventional cardiac risk factors. Although early data regarding the relationship between CVD and CKD were limited because of the need for large data sets and multivariable analysis, the importance of recognizing this complex relationship is now clear. The essence of the relationship appears to be bidirectional, and therapy directed at improving natural history of chronic disease on one system generally improves...
	Design and Rationale of a Real-Life Study to Compare Treatment Strategies for Cardiovascular Risk Factors: The CRUCIAL Study (Postgraduate Medicine) by JTE Multimedia Abstract: The CRUCIAL trial was designed to compare the relative reduction in calculated Framingham coronary heart disease risk when a multiple risk factor intervention strategy, based on single-pill amlodipine besylate/atorvastatin calcium, was compared with a usual-care strategy. Eligible patients had treated or untreated hypertension, ≥ 3 additional cardiovascular risk factors, and baseline total cholesterol ≤ 6.5 mmol/L, but no coronary heart disease. The CRUCIAL trial was a 12-month, international, multicenter, prospective, stratified, cluster-randomized, parallel-design, open-label trial conducted in 20 countries in Asia, the Middle East, Europe, and Latin America. We anticipate the results of this study will be available in mid to late 2010. In this article we report the...
	Effect of intensive lifestyle and metformin therapy on cardiovascular risk factors in patients with impaired glucose tolerance (Postgraduate Medicine) by JTE Multimedia The Diabetes Prevention Program (DPP) is the largest study to date proving that diet, exercise, and behavior modification help to prevent the development of type 2 diabetes mellitus (T2DM) in individuals at high risk. The DPP was a prospective, multicenter clinical trial in 3234 people with impaired glucose tolerance (IGT), comparing the effect of intensive lifestyle changes (diet and exercise) to treatment with standard diet and exercise combined with metformin (Diabetes Prevention Program Research Group, 2002). The intensive lifestyle changes aimed to reduce weight by 7% through a low-fat diet and 150 min of exercise per week. During the 3-year follow-up period, 29% of the placebo group developed T2DM compared with 14% of the intensive lifestyle change group and 22% of the metformin...
	Complications of Cardiovascular Procedures: Risk Factors, Management, and Bailout Techniques (Moscucci, Complications of Cardiovascular Procedures) by Mauro Moscucci (Author) Complications of Cardiovascular Procedures provides interventional cardiologists, endovascular interventionalists, and physicians in training with a comprehensive resource on the prevention and management of complications in interventional cardiology. The book focuses specifically on risk factors, prevention, and management with conventional and/or with bailout techniques and devices. It includes many images of common and rare complications and of devices.The first section, on general principles, includes quality assurance, training requirements, legal considerations, adjunctive pharmacotherapy, and conscious sedation. Subsequent sections cover general complications of invasive procedures and complications of specific coronary interventions, noncoronary cardiac interventions, peripheral...
	Causation of Cardiovascular Risk Factors in Children: Perspectives on Cardiovascular Risk in Early Life by Gerald S. Berenson (Editor)
	Smoking As a Cardiovascular Risk Factor, New Strategies for Smoking Cessation by Lars Wilhelmsen (Editor) This book directly addresses the key issues of this vexing problem. In nine very practical chapters, experts from throughout Europe explain their clinical experiences -- what works and what does not. Especially interesting for North American readers seeking a quick overview of progress elsewhere.
	Clinical Management of Cardiovascular Risk Factors in Diabetes by Moser Marvin (Author), James R. Sowers (Author) Presents the rationale for why physicians should more aggressively treat hypertension and other CV risk factors in their diabetic patients. Specific therapeutic regimens for reducing CV events in diabetic patients are presented, including BP lowering, management of lipid abnormalities, antiplatelet therapy, and glucose control.
	Atlas of Cardiovascular Risk Factors by J. Michael, M.D. Gaziano (Editor), Eugene Braunwald (Editor) Harvard Medical School, Boston, MA. Atlas provides an overview of the current knowledge on the major causative factors for heart disease and other forms of cardiovascular disease. Includes strategies to reduce the risk associated with these factors, including prevention strategies. For cardiologists. Also available in cloth. DNLM: Heart Diseases-epidemiology-Atlases.
	Cardiovascular Risk Factors in Children: The Early History of Atherosclerosis and Essential Hypertension by Gerald S. Berenson (Author)
	Cardiovascular Risk Factors by J. D. Swales (Author), David P. De Bobo (Author) In this book, genetics and ethnic background, family predisposition, sex, race and epidemiological factors in the assessment of cardiovascular risk are explained and related to cardiovascular problems. Detailed discussions of many extrinsic risk factors, including smoking, alcohol and drugs (including hormone replacement therapy and the contraceptive pill) are then given. The book also gives accounts of blood pressure and its management, and diabetes, as well as descriptions of target organ damage caused by coronary artery disease.